Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...

The application of deep learning techniques in lung nodule detection represents a significant advance in the early diagnosis and management of lung cancer. Recent developments have harnessed the power ...

Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. The research, a collaboration between BioMark's ...

Talk about a breath of fresh air. Researchers have developed a groundbreaking device that may one day make detecting lung cancer as easy as exhaling. “We built a screening tool that could allow ...

Survival outcomes in non-small cell lung cancer: Real-world analysis of immunotherapy era vs pre-immunotherapy era, with insights into treatment settings, racial disparities, and socioeconomic impacts ...

Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study Data ...

BEIJING, 4 February (BelTA - China Daily) - A Chinese research team has developed the world's first blood-based diagnostic kit that can tell whether lung nodules are benign or cancerous, including ...

Affinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy ...

Lung cancer symptoms are often non-specific, leading to late detection and misattribution to less severe conditions. The GO2 for Lung Cancer provides resources, policy advocacy, and access to clinical ...